GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: GlobeNewswire
SARASOTA, Fla. and NOVATO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced that it has dosed the first patient in its KIK-AS (Knockdown of UBE3A-antisense in Kids with Angelman Syndrome) study of GTX-102, an experimental antisense oligonucleotide being evaluated for the treatment of Angelman syndrome (AS). The Phase 1/2 open-label, multiple-dose, dose-escalating study will enroll 20 patients to evaluate the safety, tolerability, and potential efficacy of GTX-102 in pediatric patients with Angelman syndrome. This is the first investigational study testing an antisense oligonucleotide as a potential therapy to treat AS. Further details can be referenced at: https://clinicaltrials.gov/ct2/show/NCT04259281. ”Today is an important milestone with the dosing of th
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.MarketBeat
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.MarketBeat
- Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitGlobeNewswire
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.MarketBeat
RARE
Earnings
- 11/5/24 - Beat
RARE
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 8-K
- 11/6/24 - Form 10-Q
- RARE's page on the SEC website